EPO and chronic kidney disease: Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors, as a new class of agents for the therapy of anemia in CKD, increase endogenous erythropoietin and decrease serum hepcidin levels, leading to more effective internal iron metabolism without the need for excess iron administration in dialysis patients (42).